TERN-501
Appearance
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
PubChem CID | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H15Cl2N5O5 |
Molar mass | 440.24 g·mol−1 |
3D model (JSmol) | |
| |
|
TERN-501 is a selective thyromimetic drug that is being developed for the treatment of non-alcoholic fatty liver disease.[1][2]
References
[edit]- ^ Finan, Brian; Parlee, Sebastian D.; Yang, Bin (April 2021). "Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH". Molecular Metabolism. 46: 101153. doi:10.1016/j.molmet.2020.101153. PMC 8085542. PMID 33359400.
- ^ Karim, Gres; Bansal, Meena B (2023). "Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis". TouchREVIEWS in Endocrinology. 19 (1): 60–70. doi:10.17925/EE.2023.19.1.60. ISSN 2752-5457. PMC 10258622. PMID 37313239.